ProKidney (MEX:PROK) Additional Paid-In Capital : MXN881.49 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Additional Paid-In Capital?

ProKidney's quarterly additional paid-in capital declined from Sep. 2023 (MXN720.53 Mil) to Dec. 2023 (MXN613.01 Mil) but then increased from Dec. 2023 (MXN613.01 Mil) to Mar. 2024 (MXN881.49 Mil).

ProKidney's annual additional paid-in capital increased from Dec. 2021 (MXN0.00 Mil) to Dec. 2022 (MXN145.75 Mil) and increased from Dec. 2022 (MXN145.75 Mil) to Dec. 2023 (MXN613.01 Mil).

ProKidney Additional Paid-In Capital Historical Data

The historical data trend for ProKidney's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Additional Paid-In Capital Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

145.75

613.01

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial									392.80	530.72	720.53	613.01	881.49

ProKidney Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

ProKidney Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ProKidney's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (MEX:PROK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.